Table 4.

Clinical characteristics of the patients treated with Hemospray and Endoclot for lower gastrointestinal bleeding n (%)

	HS and EC (n = 17)	Hemospray (n = 9)	Endoclot (n = 7)	P value
Sex (M)	15	8	6	ns
Age, yr				0.007
mean ± SD	67.8 ± 12.2	72.9 ± 9.2	65.6 ± 9.2
range	37-81	51-81	37-76
Application as				ns
Primary therapy	10 (59)	5 (55)	4 (57.1)
Salvage therapy	7 (41.2)	4 (44)	3 (56)
Definite therapy after HP failure				ns
Coiling	0	0	0
Surgery	1 (5.9)	0	1 (14)
Comorbidities
Coagulopathy	3 (17.6)	2 (22)	1 (14)
Renal insufficiency	6 (35.3)	3 (33)	3 (43)
Hemodialysis	3 (17.6)	2 (22)	1 (14)
Liver cirrhosis	2 (11.8)	2 (22)	0
Therapeutic anticoagulation	10 (59)	3 (33)	6 (86)
Dual antiplatet therapy	1 (5.9)	0	1 (43)
Vitamin K Antagonists	3 (17.6)	0	3 (43)
DOAC	3 (17.6)	0	2 (29)
Antiaggregation therapy	5 (29.4)	2 (22)	3 (43)
Short term success	12 (79.6)	6 (67)	5 (71)	ns
Primary therapy	7 (70)	3/5 (60)	3/4 (75)
Salvage therapy	5 (71.4)	3/4 (75)	2/3 (67)
Long term success	10 (76.9)	6/7 (86)	3/5 (75)	ns
Primary therapy	6 (75)	3/4(75)	2/3 (67)
Salvage therapy	4 (57.1)	3/3 (100)	1/2 (50)
Re-bleeding rate	7 (41.2)	3 (33)	4 (57)	ns
Primary therapy	3 (30)	2/5 (40)	1/4 (25)
Salvage therapy	4 (57.1)	1/4 (25)	3/3 (100)

DOAC: Direct acting oral anticoagulant; HS: Hemospray; EC: Endoclot; HP: Hemostatic powders; HS and EC: Including patients who received both Hemospray and Endoclot at different time points.